Leading the Way in Life Science Technologies

GEN Exclusives

More »

Tutorials

More »
Feb 1, 2010 (Vol. 30, No. 3)

Cryopreserved PBMCs and Cell-Based Assays

Preserving Fundamental Characteristics for Immune Monitoring and Drug Development

  • Conclusions

    The use of standardized conditions for cryopreservation using specific media and well-monitored storage conditions in conjunction with the use of optimized thawing protocols leads to optimal preservation of fundamental characteristics of PBMCs. This enables adherence to critical requirements important in the design and execution of large-scale longitudinal or cross-sectional studies throughout drug development.

    In addition, the availability of well-characterized cryopreserved PBMCs enables ex vivo testing of leads under varying conditions. The large batch sizes contribute to consistency and reproducibility of results and provide sufficient cells that can be used as controls pertinent to a particular study. Cyropreserved PBMCs and companion assays such as ELISpot and other cell-based assays comprise a unique toolbox to facilitate progress in preclinical and clinical stages of drug development. 



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »